4-weekly avelumab plus axitinib in patients with metastatic renal cell carcinoma
Naveen S. Vasudev, Umair Aleem, Kathryn Humphries, Manon Pillai, Ben Pickwell-Smith, Christy Ralph, Satinder Jagdev, Joanne Simpson, Helen Dearden, Tom Waddell · 2026
Read 4-weekly avelumab plus axitinib in patients with metastatic renal cell carcinoma by Naveen S. Vasudev, Umair Aleem, Kathryn Humphries, Manon Pillai, Ben Pickwell-Smith, Christy Ralph, Satinder Jagdev, Joanne Simpson, Helen Dearden, Tom Waddell (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13156266.txt.
Description
Half the clinic trips for a kidney cancer pair might be spared if the drip drug could come monthly, not fortnightly. Naveen Vasudev and nine co-authors read the charts in 2026 of ninety-four folk who got the wider spacing at two centers. Half took the wide spacing from the start; half switched to it after some months on the tight one. The pair is a checkpoint drug plus a vessel-starving pill, a standard first line for spread kidney cancer.
The from-the-start group's tumors shrank in just over half of cases, and the calm held a median near two years. Harm prints matched the known lists. The switch group stayed on the wide spacing a median near seventeen months. The team call the chart tale a fair base for a true trial of the kinder calendar.
Catalog record
| CREATOR | Naveen S. Vasudev, Umair Aleem, Kathryn Humphries, Manon Pillai, Ben Pickwell-Smith, Christy Ralph, Satinder Jagdev, Joanne Simpson, Helen Dearden, Tom Waddell |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 18 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |